Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss : results from a 2-phase dietary intervention study. / Valsesia, Armand; Kulkarni, Sameer S; Marquis, Julien; Leone, Patricia; Mironova, Polina; Walter, Ondine; Hjorth, Mads Fiil; Descombes, Patrick; Hager, Jörg; Saris, Wim H; Astrup, Arne; Darimont, Christian; O'Callaghan, Nathan J.

In: American Journal of Clinical Nutrition, Vol. 109, No. 4, 2019, p. 1029-1037.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Valsesia, A, Kulkarni, SS, Marquis, J, Leone, P, Mironova, P, Walter, O, Hjorth, MF, Descombes, P, Hager, J, Saris, WH, Astrup, A, Darimont, C & O'Callaghan, NJ 2019, 'Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study', American Journal of Clinical Nutrition, vol. 109, no. 4, pp. 1029-1037. https://doi.org/10.1093/ajcn/nqy363

APA

Valsesia, A., Kulkarni, S. S., Marquis, J., Leone, P., Mironova, P., Walter, O., ... O'Callaghan, N. J. (2019). Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study. American Journal of Clinical Nutrition, 109(4), 1029-1037. https://doi.org/10.1093/ajcn/nqy363

Vancouver

Valsesia A, Kulkarni SS, Marquis J, Leone P, Mironova P, Walter O et al. Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study. American Journal of Clinical Nutrition. 2019;109(4):1029-1037. https://doi.org/10.1093/ajcn/nqy363

Author

Valsesia, Armand ; Kulkarni, Sameer S ; Marquis, Julien ; Leone, Patricia ; Mironova, Polina ; Walter, Ondine ; Hjorth, Mads Fiil ; Descombes, Patrick ; Hager, Jörg ; Saris, Wim H ; Astrup, Arne ; Darimont, Christian ; O'Callaghan, Nathan J. / Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss : results from a 2-phase dietary intervention study. In: American Journal of Clinical Nutrition. 2019 ; Vol. 109, No. 4. pp. 1029-1037.

Bibtex

@article{0b072dd2847140d2974751ded750f39b,
title = "Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss: results from a 2-phase dietary intervention study",
abstract = "Background: Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.Objective: The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.Methods: Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.Results: At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.Conclusion: In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.",
keywords = "Faculty of Science, Obesity, Insulin resistance, Low-calorie diet, Copy number, AMY1, Weight loss",
author = "Armand Valsesia and Kulkarni, {Sameer S} and Julien Marquis and Patricia Leone and Polina Mironova and Ondine Walter and Hjorth, {Mads Fiil} and Patrick Descombes and J{\"o}rg Hager and Saris, {Wim H} and Arne Astrup and Christian Darimont and O'Callaghan, {Nathan J}",
note = "CURIS 2019 NEXS 126 Copyright {\circledC} American Society for Nutrition 2019.",
year = "2019",
doi = "10.1093/ajcn/nqy363",
language = "English",
volume = "109",
pages = "1029--1037",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "4",

}

RIS

TY - JOUR

T1 - Salivary α-amylase copy number is not associated with weight trajectories and glycemic improvements following clinical weight loss

T2 - results from a 2-phase dietary intervention study

AU - Valsesia, Armand

AU - Kulkarni, Sameer S

AU - Marquis, Julien

AU - Leone, Patricia

AU - Mironova, Polina

AU - Walter, Ondine

AU - Hjorth, Mads Fiil

AU - Descombes, Patrick

AU - Hager, Jörg

AU - Saris, Wim H

AU - Astrup, Arne

AU - Darimont, Christian

AU - O'Callaghan, Nathan J

N1 - CURIS 2019 NEXS 126 Copyright © American Society for Nutrition 2019.

PY - 2019

Y1 - 2019

N2 - Background: Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.Objective: The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.Methods: Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.Results: At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.Conclusion: In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.

AB - Background: Several studies recently reported contradicting results regarding the link between amylase 1 (AMY1) copy numbers (CNs), obesity, and type 2 diabetes.Objective: The aim of this study was to assess the impact of AMY1 CN on anthropometrics and glycemic outcomes in obese individuals following a 2-phase dietary weight loss intervention.Methods: Using the paralog ratio test, AMY1 CNs were accurately measured in 761 obese individuals from the DiOGenes study. Subjects first underwent an 8-wk low-calorie diet (LCD, at 800 kcal/d) and then were randomly assigned to a 6-mo weight maintenance dietary (WMD) intervention with arms having different glycemic loads.Results: At baseline, a modest association between AMY1 CN and BMI (P = 0.04) was observed. AMY1 CN was not associated with baseline glycemic variables. In addition, AMY1 CN was not associated with anthropometric or glycemic outcomes following either LCD or WMD. Interaction analyses between AMY1 CN and nutrient intake did not reveal any significant association with clinical parameters (at baseline and following LCD or WMD) or when testing gene × WMD interactions during the WMD phase.Conclusion: In the absence of association with weight trajectories or glycemic improvements, the AMY1 CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects. This trial was registered at www.clinicaltrials.gov as NCT00390637.

KW - Faculty of Science

KW - Obesity

KW - Insulin resistance

KW - Low-calorie diet

KW - Copy number

KW - AMY1

KW - Weight loss

U2 - 10.1093/ajcn/nqy363

DO - 10.1093/ajcn/nqy363

M3 - Journal article

C2 - 30982860

VL - 109

SP - 1029

EP - 1037

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 4

ER -

ID: 216822857